Related references
Note: Only part of the references are listed.Using poison center exposure calls to predict prescription opioid abuse and misuse-related emergency department visits
Jonathan M. Davis et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2014)
A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers
Suzanne K. Vosburg et al.
ADDICTION (2013)
Pharmaceutical Overdose Deaths, United States, 2010
Christopher M. Jones et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Crowdsourcing Black Market Prices For Prescription Opioids
Nabarun Dasgupta et al.
JOURNAL OF MEDICAL INTERNET RESEARCH (2013)
Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations
Shannon M. Smith et al.
PAIN (2013)
Synergistic Interaction between the Two Mechanisms of Action of Tapentadol in Analgesia
W. Schroeder et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
(-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (Tapentadol HCl):: a novel μ-opioid receptor agonist norepinephrine Reuptake inhibitor with broad-spectrum analgesic properties
Thomas M. Tzschentke et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Prescription opioid abuse among enrollees into methadone maintenance treatment
Andrew Rosenblum et al.
DRUG AND ALCOHOL DEPENDENCE (2007)
Share Paper
